ddregpharmau
Navigating the New Normal: Pharmacovigilance and Regulatory Trends in the UK (2026)
In the world of life sciences, the UK has always been a titan. However, as we move through 2026, the “Standard Operating Procedure” has changed. With the full implementation of the Windsor Framework and recent updates to pharmacovigilance regulations, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is carving a path that is both independent of […]
Navigating the New Normal: Pharmacovigilance and Regulatory Trends in the UK (2026)
In the world of life sciences, the UK has always been a titan. However, as we move through 2026, the “Standard Operating Procedure” has changed. With the full implementation of the Windsor Framework and recent updates to pharmacovigilance regulations, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is carving a path that is both […]
Ensuring Drug Safety Down Under: The Critical Role of Pharmacovigilance in Australia
For pharmaceutical manufacturers, sponsors, and life sciences organizations operating in the Australian market, ensuring the ongoing safety of therapeutic goods is not just a best practice—it is a mandatory obligation. The moment a medicine is approved and listed on the Australian Register of Therapeutic Goods (ARTG), the post-market safety surveillance begins, overseen by the demanding […]